Bristol Myers Squibb Presents New Clinical Trial And Real-World Data For Camzyos At ACC Annual Scientific Session & Expo

Bristol Myers Squibb (NYSE: BMY) presented new clinical trial and real-world data for Camzyos (mavacamten) at the ACC Annual Scientific Session & Expo, highlighting positive Phase 3 results from the SCOUT-HCM trial. This trial indicates the potential of Camzyos to be the first cardiac myosin inhibitor for treating adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Additionally, new real-world evidence supports the long-term efficacy and safety of Camzyos across diverse patient populations in oHCM.